



CS/NSE&BSE/UFR/2016-17  
August 10, 2016

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Stock Code: SUVEN–EQ**

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**Stock Code: 530239**

Dear Sir/Madam,

**Sub: Notification of Un-audited Financial Results for the quarter ended 30th June, 2016**

.....

With reference to the above subject, pursuant to Regulation 33 read with regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. **Wednesday, 10th August, 2016**, has taken on record the Standalone **Un-audited Financial Results of the Company for the quarter ended 30th June, 2016**.

We are enclosing herewith the Un-audited Financial Results for the quarter ended 30th June, 2016 along with **Limited Review Report of Statutory Auditors of the Company**.

We hereby notify that in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 our Company will submit standalone financial results for the financial year 2016-2017.

Please find enclosed **Press release** of our company. We request you to take these documents on your records.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao'.

**K Hanumantha Rao**  
Company Secretary

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



**SUVEN LIFE SCIENCES LTD**

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvен.com website: www.suven.com

**STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2016**

PART - I				Rs. In lakhs	
Sl. No.	PARTICULARS	For the Quarter Ended			Previous Year Ended
		30/06/2016	31/03/2016	30/06/2015	31/03/2016
		Un-audited	Un-audited	Un-audited	Un-audited
1	<b>Income from operations</b>				
	(a) Net sales/income from operations	13,322.70	16,937.20	10,117.26	50,028.18
	(b) Other operating income	-	-	-	-
	<b>Total income from operations (net)</b>	<b>13,322.70</b>	<b>16,937.20</b>	<b>10,117.26</b>	<b>50,028.18</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	3,985.98	4,664.34	3,868.64	17,845.37
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(36.77)	1,925.08	(1,024.15)	(1,205.21)
	d) Employee benefits expense	1,146.96	926.49	936.92	4,094.43
	e) Depreciation and amortisation expense	480.58	479.82	290.46	1,672.04
	f) Other expenses - Manufacturing Exps	1,741.04	2,172.22	1,581.58	7,522.00
	- R & D Exps	1,469.01	1,678.24	1,593.61	6,295.09
	- Others	673.07	784.16	609.17	2,597.22
	<b>Total expenses</b>	<b>9,459.87</b>	<b>12,630.35</b>	<b>7,856.23</b>	<b>38,820.94</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>3,862.83</b>	<b>4,306.85</b>	<b>2,261.03</b>	<b>11,207.24</b>
4	Other Income	449.70	455.33	514.30	1,961.51
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>	<b>4,312.53</b>	<b>4,762.18</b>	<b>2,775.33</b>	<b>13,168.75</b>
6	Finance costs	159.56	167.52	103.47	587.21
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>	<b>4,152.97</b>	<b>4,594.66</b>	<b>2,671.86</b>	<b>12,581.54</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit/Loss from Ordinary Activities before tax (7 ± 8)</b>	<b>4,152.97</b>	<b>4,594.66</b>	<b>2,671.86</b>	<b>12,581.54</b>
10	Tax Expenses	895.36	876.86	611.66	2,573.55
11	<b>Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)</b>	<b>3,257.61</b>	<b>3,717.80</b>	<b>2,060.20</b>	<b>10,007.99</b>
12	Extraordinary Items (net of tax expense ₹ ____ Lakhs)	-	-	-	-
13	<b>Net Profit (+)/Loss(-) for the period (11 ± 12)</b>	<b>3,257.61</b>	<b>3,717.80</b>	<b>2,060.20</b>	<b>10,007.99</b>
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority interest *	-	-	-	-
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *</b>	<b>3,257.61</b>	<b>3,717.80</b>	<b>2,060.20</b>	<b>10,007.99</b>
16.a	Other Comprehensive Income	(11.30)	(11.30)	(11.30)	(45.22)
16.b	<b>Total Comprehensive Income</b>	<b>3,246.31</b>	<b>3,706.50</b>	<b>2,048.90</b>	<b>9,962.77</b>
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				61,074.42
19.i	<b>Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):</b>				
	a) Basic	2.56	2.92	1.62	7.86
	b) Diluted	2.56	2.92	1.62	7.86
19.ii	<b>Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):</b>				
	a) Basic	2.56	2.92	1.62	7.86
	b) Diluted	2.56	2.92	1.62	7.86
<b>PART - II</b>					
		30/06/2016	31/03/2016	30/06/2015	31/03/2016


A PARTICULARS OF SHAREHOLDING					
1	Public share holdings				
	- Number of shares	50,912,478	50,912,478	51,624,902	50,912,478
	- Percentage of Share holding	40.00%	40.00%	40.56%	40.00%
2	Promoters and promoter group Shareholding**				
a)	Pledged / Encumbered	NIL	NIL	NIL	NIL
	- Number of shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
b)	Non-Encumbered	76,370,000	76,370,000	75,657,576	76,370,000
	- Number of shares				
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	60.00%	60.00%	59.44%	60.00%
Particulars		30/06/2016			
B INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	0			
	Received during the quarter	30			
	Disposed of during the quarter	30			
	Remaining unresolved at the end of the quarter	0			

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED					Rs.In Lacs		
PARTICULARS	For the Quarter Ended			Year Ended			
	30/06/2016	31/03/2016	30/06/2015	31/03/2016			
	Un-audited	Un-audited	Un-audited	Un-audited			
1	<b>SEGMENT REVENUE :-</b>						
a)	Manufacturing (CRAMS)	12,766.39	16,420.56	9,590.65	46,786.81		
b)	Services (DDDSS)	556.31	516.64	526.61	3,241.37		
c)	Research & Development	-	-	-	-		
	<b>Net Sales from Operations</b>	<b>13,322.70</b>	<b>16,937.20</b>	<b>10,117.26</b>	<b>50,028.18</b>		
2	<b>SEGMENT RESULTS :-</b>						
	Profit/(Loss) before tax and interest:						
a)	Manufacturing (CRAMS)	5,596.76	6,213.66	4,066.63	17,391.75		
b)	Services (DDDSS)	258.68	307.44	236.79	1,982.52		
c)	Research & Development	(1,469.01)	(1,678.23)	(1,593.61)	(6,295.08)		
	<b>TOTAL</b>	<b>4,386.43</b>	<b>4,842.87</b>	<b>2,709.81</b>	<b>13,079.19</b>		
Less:	i) Interest	113.26	109.93	64.19	406.52		
	ii) Other Un-allocable exps net off un-allocable Income	120.20	138.28	(26.24)	91.13		
	<b>Total Profit Before Tax</b>	<b>4,152.97</b>	<b>4,594.66</b>	<b>2,671.86</b>	<b>12,581.54</b>		
3	<b>SEGMENT ASSETS :</b>						
a)	Manufacturing (CRAMS)	43,126.18	43,026.99	39,125.41	43,026.99		
b)	Services (DDDSS)	3,700.16	3,879.73	4,264.40	3,879.73		
c)	Research & Development	2,423.33	2,626.80	2,566.06	2,626.80		
d)	Un allocated	30,681.23	27,816.55	31,611.29	27,816.55		
	<b>TOTAL</b>	<b>79,930.90</b>	<b>77,350.07</b>	<b>77,567.16</b>	<b>77,350.07</b>		
	<b>SEGMENT LIABILITIES :</b>						
a)	Manufacturing (CRAMS)	7,764.83	7,838.84	7,482.65	7,838.84		
b)	Services (DDDSS)	322.33	335.70	392.57	335.70		
c)	Research & Development	1,590.97	1,678.72	2,158.66	1,678.72		
d)	Un allocated	617.21	547.38	661.11	547.38		
	<b>TOTAL</b>	<b>10,295.34</b>	<b>10,400.64</b>	<b>10,694.99</b>	<b>10,400.64</b>		

- Notes: 1) The above results were reviewed by Audit committee and approved by the Board of Directors' meeting held on 10th August 2016  
2) Corresponding Previous period figures have been regrouped / reclassified whenever necessary.  
3) The statutory auditors has reviewed the financial results for the quarter ended 30th June 2016. The financial results for the quarter ended 30th June 2015, 31st March 2016 & year ended 31st March 2016 are not subject to review or audit.  
4) Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the Quarters/Year presented as under.

	Quarter ended		Year ended
	31/03/2016	30/06/2015	31/03/2016
Net profit under previous GAAP (After Tax)	3,229.11	2,023.07	9,496.98
QIP issue expenses considered for grossing up to share premium account	484.68	30.29	484.68
Transitional effect on account of fair valuation of govt loans and reclassification of actuarial loss on employee benefit	9.43	12.83	50.13
Deferred tax asset due to fair valuation of Mutual funds & actuarial loss on employee benefits	(5.42)	(5.99)	(23.80)
<b>Net profit under Ind AS (After Tax)</b>	<b>3,717.80</b>	<b>2,060.20</b>	<b>10,007.99</b>
Other Comprehensive Income	(11.30)	(11.30)	(45.22)
<b>Total Comprehensive Income Under Ind AS</b>	<b>3,706.50</b>	<b>2,048.90</b>	<b>9,962.77</b>

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place : Hyderabad  
Date: 10th August 2016

**We Deliver**



Ref No.LR/001/2016-17

**LIMITED REVIEW REPORT**

To

The Board of Directors of  
SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of SUVEN LIFE SCIENCES LIMITED, having registered office at SDE Serene Chambers, 6<sup>th</sup> Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the period ended on 30.06.2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Ind AS compliant figures of the quarter ended 31.03.2016 and 30.06.2015 and year ended 31.03.2016 have not been subjected to a limited review or audit and are based on previously published financial results as adjusted for differences arising on the transition to Indian Accounting Standards (Ind AS), which have been prepared solely based on the information compiled by the Management.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **KARVY & CO.**,  
Chartered Accountants  
(Firm Registration No.001757S)

  
**(K. AJAY KUMAR)**  
PARTNER  
M.No.021989



Place: Hyderabad  
Date: 10.08.2016

## News Release

### ***Suven's Income at Rs. 1377 Mn; PAT at Rs. 326 Mn for the 1st quarter ended June 2016***

**HYDERABAD, INDIA (10th August, 2016)** – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2016. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 10th August 2016 at Hyderabad.

Financial Highlights for the 1<sup>st</sup> Quarter ended June' 2016 vs 1<sup>st</sup> Qtr ended June 2015

<b>Growth in revenue</b>	<b>Rs 1377 Mn vs. Rs 1060 Mn</b>	<b>- Up by 29.54%</b>
<b>Growth in PAT</b>	<b>Rs 326 Mn vs. Rs 206 Mn</b>	<b>- up by 58.12%</b>
<b>Growth in EBIDTA</b>	<b>Rs 479 Mn vs. Rs 307 Mn</b>	<b>- up by 56.34%</b>

Financial Highlights for the 1<sup>st</sup> Quarter ended June' 2016: (QoQ)

<b>Growth in revenue</b>	<b>Rs 1377 Mn vs. Rs 1694 Mn</b>	<b>- Down by 20.81%</b>
<b>Growth in PAT</b>	<b>Rs 326 Mn vs. Rs 372 Mn</b>	<b>- Down by 12.38%</b>
<b>Growth in EBIDTA</b>	<b>Rs 479 Mn vs. Rs 524 Mn</b>	<b>- Down by 8.56%</b>

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 147 Mn (10.67% on revenue) for the quarter ended 30<sup>th</sup> June 2016.

**For more information on Suven please visit our Web site at <http://www.suven.com>**

*Risk Statement:*

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)